Trial Profile
A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms WEE WIN
- 10 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2026.
- 10 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2026.
- 31 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.